JAC Advance Access originally published online on November 18, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2002) 50, 1027-1030
© 2002 The British Society for Antimicrobial Chemotherapy
Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum
1 Third Paediatric Department, Aristotle University, Hippokration Hospital, Thessaloniki GR-54642; 2 First Propedeutic Department of Medicine, Athens University, Athens GR-11527, Greece; 3 Immunocompromised Host Section, Paediatric Oncology Branch, National Cancer Institute, Building 10, Room 13N240, Bethesda, MD 20892, USA
Received 29 July 2002; accepted 9 August 2002
Scedosporium prolificans and Scedosporium apiospermum are resistant to most antifungal agents and cause refractory pulmonary and disseminated infections. The combined effects of deoxycholate amphotericin B, amphotericin B lipid complex and liposomal amphotericin B with human polymorphonuclear leucocytes (PMNs) in damaging hyphae of these fungi were evaluated by XTT assay. Amphotericin B lipid complex displayed a significant additive effect with PMNs against both Scedosporium species (22% for S. prolificans and 81% for S. apiospermum; P < 0.04). None of the formulations adversely affected the PMN antifungal activity. These findings may be important in designing better strategies for management of infections due to these organisms.
Keywords: amphotericin B formulations, Scedosporium, polymorphonuclear leucocytes
* Corresponding author. Tel: +1-301-402-0023; Fax: +1-301-402-0575; E-mail: walsht{at}mail.nih.gov
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. Dotis, M. Simitsopoulou, M. Dalakiouridou, T. Konstantinou, C. Panteliadis, T. J. Walsh, and E. Roilides Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus J. Antimicrob. Chemother., April 1, 2008; 61(4): 810 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Cortez, E. Roilides, F. Quiroz-Telles, J. Meletiadis, C. Antachopoulos, T. Knudsen, W. Buchanan, J. Milanovich, D. A. Sutton, A. Fothergill, et al. Infections Caused by Scedosporium spp. Clin. Microbiol. Rev., January 1, 2008; 21(1): 157 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dotis, M. Simitsopoulou, M. Dalakiouridou, T. Konstantinou, A. Taparkou, F. Kanakoudi-Tsakalidou, T. J. Walsh, and E. Roilides Effects of Lipid Formulations of Amphotericin B on Activity of Human Monocytes against Aspergillus fumigatus Antimicrob. Agents Chemother., March 1, 2006; 50(3): 868 - 873. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Mukherjee, D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum Combination Treatment of Invasive Fungal Infections Clin. Microbiol. Rev., January 1, 2005; 18(1): 163 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bellocchio, S. Moretti, K. Perruccio, F. Fallarino, S. Bozza, C. Montagnoli, P. Mosci, G. B. Lipford, L. Pitzurra, and L. Romani TLRs Govern Neutrophil Activity in Aspergillosis J. Immunol., December 15, 2004; 173(12): 7406 - 7415. [Abstract] [Full Text] [PDF] |
||||



